Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Neoplasms 14 Venous Thromboembolism 11 Venous Thrombosis 4 Thrombosis 3 Pulmonary Embolism 3 Multiple Myeloma 3 Upper Extremity Deep Vein Thrombosis 2 Lung Neoplasms 2 Colonic Neoplasms 2 Carcinoma, Hepatocellular 2 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Urogenital Neoplasms 1 Thromboembolism 1 Stomach Neoplasms 1 Recurrence 1 Prostatic Neoplasms 1 Prevention of Venous Thromboembolism 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Myeloproliferative Disorders 1 Lymphoma 1 Leukemia 1 Inflammation 1 Immune System Diseases 1 Hemorrhage 1 Hematologic Neoplasms 1 Glioma 1 Gastrointestinal Stromal Tumors 1

Interventions

Cyclophosphamide 81 fludarabine phosphate 77 Peripheral Blood Stem Cell Transplantation 62 Mycophenolic Acid 55 Tacrolimus 54 Whole-Body Irradiation 52 Busulfan 51 Antilymphocyte Serum 45 Cyclosporine 41 fludarabine 36 Methotrexate 32 Filgrastim 32 Melphalan 30 Radiotherapy 25 Methylprednisolone 19 Cytarabine 17 Cord Blood Stem Cell Transplantation 17 Sirolimus 15 Azacitidine 15 Granulocyte Colony-Stimulating Factor 14 Alemtuzumab 14 thymoglobulin 13 Flow Cytometry 13 Etoposide 13 Cyclosporins 13 Specimen Handling 10 Biopsy 10 Thiotepa 9 Psychiatric Rehabilitation 9 Decitabine 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Myeloproliferative Disorders × Rivaroxaban × Clear all

NCT04192916 2021-02-21

MPN-DOACs

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡